Pharmaceuticals

Xerostomia Therapeutics Industry Growth Insights: Revenue Forecast to 2030

February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the xerostomia therapeutics market from 2026–2035 with trusted insights from The Business Research Company

How much is the Xerostomia Therapeutics Market valued at in 2026, and what valuation is forecast for 2030?

The xerostomia therapeutics market has experienced consistent expansion in recent years. It is projected to grow from $2.24 billion in 2025 to $2.35 billion in 2026, at a compound annual growth rate (CAGR) of 5.0%. Historically, this growth has been driven by factors including the aging population, widespread use of xerogenic drugs, rising prevalence of chronic diseases, increased dental awareness, and hospital-based symptom management.

The xerostomia therapeutics market is projected to experience consistent expansion in the coming years, with its size anticipated to reach $2.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This anticipated growth during the forecast period is driven by factors such as enhanced availability of over-the-counter (OTC) products, the rise in side effects from cancer therapies, evolving self-medication practices, the widening reach of pharmacy networks, and an increased emphasis on quality of life treatments. Key developments expected in the forecast period involve a higher occurrence of medication-induced dry mouth, an escalating need for over-the-counter treatments, greater uptake of artificial saliva solutions, the expansion of both retail and mail-order pharmacy services, and a heightened focus on managing oral symptoms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

What Drivers Are Influencing The Growth Of The Xerostomia Therapeutics Market?

The increasing occurrence of chronic diseases is anticipated to fuel the expansion of the xerostomia therapeutics market. Chronic diseases are defined as prolonged medical conditions that persist for many months or years, often developing gradually and necessitating continuous care. The primary reason behind the growing incidence of chronic diseases is sedentary lifestyles, as a lack of regular physical activity contributes to conditions such as obesity, cardiovascular problems, and diabetes. Xerostomia therapeutics support individuals with chronic diseases by relieving symptoms of dry mouth, thereby enhancing oral health, nutritional intake, and adherence to medication, all of which are vital for managing long-term ailments. For example, according to the UK-based government department National Health Service in June 2024, 3,615,330 individuals registered with a general practitioner were identified with non-diabetic hyperglycemia or pre-diabetes (a condition characterized by elevated blood sugar levels, not yet meeting the criteria for diabetes) in 2023. This figure represents an 18% increase from 3,065,825 cases recorded in 2022. Consequently, the rising prevalence of chronic diseases is propelling the growth of the xerostomia therapeutics market.

How Is The Xerostomia Therapeutics Market Organized Into Various Segments?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

Which Trends Are Influencing The Development Of The Xerostomia Therapeutics Market?

Leading companies in the xerostomia therapeutics market are prioritizing non-invasive, patient-friendly treatments, such as oral sprays designed to offer precise topical lubrication and a protective barrier throughout the mouth to alleviate dry-mouth symptoms and support overall oral health. These oral sprays for xerostomia are formulations delivered as a fine mist directly onto the oral mucosa (tongue, palate, inner cheeks), forming either a hydrating film or a lipid-based coating. This action aims to reduce moisture evaporation, enhance lubrication during activities like chewing, swallowing, and speaking, and provide longer-lasting relief for patients experiencing dry mouth. For instance, in July 2023, K Pharmaceuticals, a US-based pharmaceutical company, introduced Aquoral. This clinically-proven oral spray for xerostomia utilizes patented Oxidized Glycerol Triesters (OGT) lipid technology to establish a long-lasting protective barrier over the oral cavity, delivering up to six hours of relief with just two quick sprays, and thereby reducing the need for frequent reapplication compared to aqueous-based treatments.

Who Are The Top-Performing Companies In The Xerostomia Therapeutics Market In Recent Years?

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Xerostomia Therapeutics Market?

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Xerostomia Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15700&type=smp

Browse Through More Reports Similar to the Global Xerostomia Therapeutics Market 2026, By The Business Research Company

Xerostomia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Mantle Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mantle-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795